Skip to main content
Erschienen in: Supportive Care in Cancer 9/2012

01.09.2012 | Original Article

Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone

verfasst von: Christoph Ostgathe, Raymond Voltz, Annika Van Aaaken, Carsten Klein, Rainer Sabatowski, Friedemann Nauck, Jan Gaertner

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

An algorithm to convert from any other opioid to oral levo-methadone was developed in Germany, the German model of levo-methadone conversion (GMLC). According to this GMLC, the pre-existing opioid is stopped, then titration of oral levo-methadone is initiated with a starting dose of 5 mg orally q 4 h (plus prn q 1 h). If necessary, levo-methadone dose is increased (pain) or decreased (side effects) by 30% q 4 h (plus prn q 1 h). After 72 h, the achieved single dose is maintained, but the dosing interval increases twofold to q 8 h (plus prn q 3 h). The aim of this study was to obtain information about the practicability, safety, and efficacy of the GMLC in clinical routine.

Methods

A retrospective, systematic chart review of levo-methadone conversions for the treatment of pain in inpatient palliative care was performed.

Results

Fifty-two patients were analyzed. The dosing interval was increased correctly after 72 h as demanded by the GMLC in 60% of patients. In 85% of the patients, opioid medication with levo-methadone could be maintained until the end of the inpatient stay. In three patients (6%), levo-methadone administration had to be stopped due to side effects. No serious adverse events could be detected during opioid rotation. Pain intensity was reduced significantly (p < 0.001) after conversion concerning mean (NRS 0.9; range 0–4) and maximum pain over the day (NRS 3.9; range 0–10).

Conclusion

The presented study indicates that the GMLC provides a practical and reasonably safe approach to perform opioid rotation to levo-methadone in a palliative care setting.
Literatur
1.
Zurück zum Zitat Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, Deglon JJ, Faouzi M, Scherbaum N, Eap CB (2010) Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 170:529–536PubMedCrossRef Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, Deglon JJ, Faouzi M, Scherbaum N, Eap CB (2010) Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 170:529–536PubMedCrossRef
2.
Zurück zum Zitat Bausewein C, Remi C, Twycross R, Wilcock A (2005) Arzneimitteltherapie in der Palliativmedizin. Urban & Fischer Verlag, München Bausewein C, Remi C, Twycross R, Wilcock A (2005) Arzneimitteltherapie in der Palliativmedizin. Urban & Fischer Verlag, München
3.
Zurück zum Zitat Benitez-Rosario MA, Salinas-Martin A, Aguirre-Jaime A, Perez-Mendez L, Feria M (2009) Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 37:1061–1068PubMedCrossRef Benitez-Rosario MA, Salinas-Martin A, Aguirre-Jaime A, Perez-Mendez L, Feria M (2009) Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. J Pain Symptom Manage 37:1061–1068PubMedCrossRef
4.
Zurück zum Zitat Bruera E, Pereira J, Watanabe S (1996) Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef Bruera E, Pereira J, Watanabe S (1996) Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef
5.
Zurück zum Zitat Bruera E, Sweeney C (2002) Methadone use in cancer patients with pain: a review. J Palliat Med 5:127–138PubMedCrossRef Bruera E, Sweeney C (2002) Methadone use in cancer patients with pain: a review. J Palliat Med 5:127–138PubMedCrossRef
6.
Zurück zum Zitat Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73–83PubMedCrossRef Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73–83PubMedCrossRef
8.
Zurück zum Zitat Gaertner J, Voltz R, Ostgathe C (2008) Methadone: a closer look at the controversy. J Pain Symptom Manage 36:e4–e7PubMedCrossRef Gaertner J, Voltz R, Ostgathe C (2008) Methadone: a closer look at the controversy. J Pain Symptom Manage 36:e4–e7PubMedCrossRef
9.
Zurück zum Zitat Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F (2005) Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19:477–484PubMedCrossRef Klepstad P, Kaasa S, Cherny N, Hanks G, de Conno F (2005) Pain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research Network. Palliat Med 19:477–484PubMedCrossRef
10.
Zurück zum Zitat Krantz MJ, Mehler PS (2006) QTc prolongation: methadone's efficacy-safety paradox. Lancet 368:556–557PubMedCrossRef Krantz MJ, Mehler PS (2006) QTc prolongation: methadone's efficacy-safety paradox. Lancet 368:556–557PubMedCrossRef
11.
Zurück zum Zitat Lin C, Somberg T, Molnar J, Somberg J (2009) The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiol 113:59–65CrossRef Lin C, Somberg T, Molnar J, Somberg J (2009) The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiol 113:59–65CrossRef
12.
Zurück zum Zitat Mancini I, Lossignol DA, Body JJ (2000) Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 12:308–313PubMedCrossRef Mancini I, Lossignol DA, Body JJ (2000) Opioid switch to oral methadone in cancer pain. Curr Opin Oncol 12:308–313PubMedCrossRef
13.
Zurück zum Zitat Morley JS, Makin MK (1998) The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 5:51–58CrossRef Morley JS, Makin MK (1998) The use of methadone in cancer pain poorly responsive to other opioids. Pain Reviews 5:51–58CrossRef
14.
Zurück zum Zitat Nauck F, Ostgathe C, Dickerson ED (2001) A German model for methadone conversion. Am J Hosp Palliat Care 18:200–202PubMedCrossRef Nauck F, Ostgathe C, Dickerson ED (2001) A German model for methadone conversion. Am J Hosp Palliat Care 18:200–202PubMedCrossRef
15.
Zurück zum Zitat Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwohner K, Schulenberg D, Radbruch L (2004) Drugs in palliative care: results from a representative survey in Germany. Palliat Med 18:100–107PubMedCrossRef
16.
Zurück zum Zitat Ostgathe C, Gaertner J, Nauck F, Voltz R (2008) High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage 35:229–231PubMedCrossRef Ostgathe C, Gaertner J, Nauck F, Voltz R (2008) High dose levo-methadone treatment for cancer pain in a patient with a history of drug addiction. J Pain Symptom Manage 35:229–231PubMedCrossRef
17.
Zurück zum Zitat Ostgathe C, Radbruch L, Nauck F, Elsner F (2007) Cancer pain management. Zeitschrift für Palliativmedizin 8:13–30CrossRef Ostgathe C, Radbruch L, Nauck F, Elsner F (2007) Cancer pain management. Zeitschrift für Palliativmedizin 8:13–30CrossRef
18.
Zurück zum Zitat Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ (2011) Morphine to methadone conversion: an interpretation of published data. Am J Hosp Palliat Care 28:135–140PubMedCrossRef Pollock AB, Tegeler ML, Morgan V, Baumrucker SJ (2011) Morphine to methadone conversion: an interpretation of published data. Am J Hosp Palliat Care 28:135–140PubMedCrossRef
19.
Zurück zum Zitat Ripamonti C, Dickerson ED (2001) Strategies for the treatment of cancer pain in the new millennium. Drugs 61:955–977PubMedCrossRef Ripamonti C, Dickerson ED (2001) Strategies for the treatment of cancer pain in the new millennium. Drugs 61:955–977PubMedCrossRef
20.
Zurück zum Zitat Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216–3221PubMed Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16:3216–3221PubMed
21.
Zurück zum Zitat Ripamonti C, Groff L, Brunelli C, Polastri D, Stravakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 16(10):3216–3221PubMed Ripamonti C, Groff L, Brunelli C, Polastri D, Stravakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 16(10):3216–3221PubMed
22.
Zurück zum Zitat Tse DM, Sham MM, Ng DK, Ma HM (2003) An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 17:206–211PubMedCrossRef Tse DM, Sham MM, Ng DK, Ma HM (2003) An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population. Palliat Med 17:206–211PubMedCrossRef
23.
Zurück zum Zitat Watanabe S (2001) Methadone: the renaissance. J Palliat Care 17:117–120PubMed Watanabe S (2001) Methadone: the renaissance. J Palliat Care 17:117–120PubMed
24.
Zurück zum Zitat Weschules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9:595–612PubMedCrossRef Weschules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9:595–612PubMedCrossRef
Metadaten
Titel
Practicability, safety, and efficacy of a “German model” for opioid conversion to oral levo-methadone
verfasst von
Christoph Ostgathe
Raymond Voltz
Annika Van Aaaken
Carsten Klein
Rainer Sabatowski
Friedemann Nauck
Jan Gaertner
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1320-8

Weitere Artikel der Ausgabe 9/2012

Supportive Care in Cancer 9/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.